Comparison
Testosterone vs TUDCA
Side-by-side of Testosterone and TUDCA. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Testosterone
Testosterone replacement therapy for hypogonadism: TRAVERSE 2023 cardiovascular data, cypionate dosing, body composition gains, Schedule III status.
TUDCA
TUDCA is the taurine-conjugated form of ursodeoxycholic acid, a bile-acid molecule with replicated effects on liver function, ER stress, and bile flow.
Effects at a glance
Testosterone
- •Primary androgen; FDA approved for hypogonadism with confirmed deficiency and symptoms
- •Testosterone Trials (2016) showed sexual function and bone density improvements in older hypogonadal men
- •TRAVERSE 2023 (n=5,246) found non-inferiority on MACE versus placebo, with higher AF and PE rates
- •Schedule III controlled substance in US; WADA banned in sport
- •Aromatizes to estradiol; converts to DHT via 5-alpha reductase; both metabolites matter clinically
- •Erythrocytosis (HCT above 54%) affects 5 to 25% of users and is the most common dose-limiting effect
TUDCA
- •Bile-acid molecule (taurine-conjugated UDCA) with chemical chaperone activity at the endoplasmic reticulum
- •Established pharmaceutical use for cholestasis and primary biliary cholangitis at 500-750 mg/day
- •Reduces ER stress and stabilizes misfolded proteins; the mechanistic basis for emerging ALS / retinal applications
- •Modest improvements in NAFLD markers and insulin sensitivity at 500-1,750 mg/day in small trials
- •Mitochondrial protection signal in animal models drives the longevity-supplement positioning
- •Generally well-tolerated; mild GI effects are the main dose-dependent issue
Side-by-side
| Attribute | Testosterone | TUDCA |
|---|---|---|
| Category | hormone | supplement |
| Also known as | TRT, testosterone replacement therapy, testosterone cypionate, testosterone enanthate, Androgel, Testim | tauroursodeoxycholic acid, taurine-conjugated UDCA |
| Half-life (hr) ↗ | 192 | 4 |
| Typical dose (mg) ↗ | 150 | 500 |
| Dosing frequency | weekly to twice-weekly (cypionate/enanthate IM or SC); daily (topical, oral); every 3 to 6 months (pellet) | daily, divided into 2 doses with food |
| Routes | intramuscular, subcutaneous, topical, buccal, subcutaneous (pellet), oral | oral |
| Onset (hr) | 24 | 1 |
| Peak (hr) | 72 | 2 |
| Molecular weight | 288.42 | 499.7 |
| Molecular formula | C19H28O2 | C26H45NO6S |
| Mechanism | Androgen receptor agonist driving anabolic gene transcription in muscle, bone, brain, and androgen-sensitive tissue. Aromatized to estradiol and 5-alpha-reduced to DHT, both with distinct downstream effects. | Bile-acid signaling via FXR/TGR5 receptors; chemical chaperone reducing ER stress and unfolded protein response; mitochondrial protection through reduced outer-membrane permeabilization. |
| Legal status | Schedule III controlled substance (US); WADA banned | OTC dietary supplement (US); pharmaceutical in Italy and several Asian countries |
| WADA status | banned | allowed |
| DEA / Rx | Schedule III | OTC supplement |
| Pregnancy | Category X; contraindicated in pregnancy (virilizing effect on female fetus) | Insufficient data for supplement use; UDCA used in cholestasis of pregnancy |
| CAS | 58-22-0 | 14605-22-2 |
| PubChem CID | 6013 | 9848818 |
| Wikidata | Q150726 | Q418751 |
Safety profile
Testosterone
Common side effects
- erythrocytosis
- acne
- oily skin
- fluid retention
- increased body hair
- fertility suppression
- injection-site reactions
Contraindications
- active prostate cancer
- active breast cancer
- untreated severe sleep apnea
- untreated severe BPH
- uncontrolled heart failure
- polycythemia at baseline
Interactions
- warfarin: may potentiate anticoagulant effect; monitor INR(moderate)
- insulin: may improve insulin sensitivity; monitor glucose in diabetics(moderate)
- 5-alpha reductase inhibitors (finasteride): blocks DHT conversion; reduces some androgen effects(moderate)
- aromatase inhibitors (anastrozole): lowers estradiol; risk of over-suppression(moderate)
TUDCA
Common side effects
- mild GI upset
- diarrhea (dose-dependent)
- constipation (rare)
- nausea
Contraindications
- complete biliary obstruction
- pregnancy / lactation (insufficient supplement-dose data)
- active GI disease without medical supervision
Interactions
- cyclosporine, oral contraceptives, fat-soluble vitamins: modest absorption changes via altered bile-acid pool(minor)
- phenylbutyrate: synergistic for ALS use (Relyvrio combination); consult clinician(moderate)
Which Should You Take?
TUDCA comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Testosterone is the right call when one of the conditionals below applies.
- → If your priority is hormonal optimization, pick Testosterone.
- → If your priority is sexual function, pick Testosterone.
- → If your priority is liver function, pick TUDCA.
- → If your priority is healthspan extension, pick TUDCA.
Edge case: If you want to avoid controlled substance, TUDCA is the more accessible choice.
Default choice: TUDCA. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Testosterone only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Testosterone and TUDCA?
Testosterone and TUDCA differ in category (hormone vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Testosterone or TUDCA?
Testosterone half-life is 192 hours; TUDCA half-life is 4 hours.
Can you stack Testosterone with TUDCA?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper